The Technical Analyst
Bioxytran, Inc. [BIXT]
Exchange: PNK
Bioxytran, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.95% $0.101
America/New_York / 3 mai 2024 @ 15:47
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 14.62 mill |
| EPS: | -0.0300 |
| P/E: | -3.37 |
| Earnings Date: | Nov 09, 2023 |
| SharesOutstanding: | 144.64 mill |
| Avg Daily Volume: | 0.109 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.37 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.17x |
| Company: PE -3.37 | industry: PE 19.64 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0162 (-116.07%) $-0.117 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0881 - 0.114 ( +/- 12.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-19 | Milanova Radka | Buy | 70 423 | common |
| 2024-04-19 | Conaway Dale H | Buy | 70 423 | common |
| 2024-04-19 | Hoberman Alan M | Buy | 70 423 | common |
| 2024-04-19 | Milanova Radka | Sell | 0 | common |
| 2024-03-27 | Utter Anders | Buy | 266 955 | common |
| INSIDER POWER |
|---|
| 90.03 |
| Last 84 transactions |
| Buy: 33 376 843 | Sell: 11 429 961 |
Forecast:
16:00 - $0.101
Live Trading Signals (every 1 min)
Forecast
1: 15:57 - $0.101
Forecast 2: 16:00 - $0.101
Forecast 3: 16:00 - $0.101
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.101 (0.95% ) |
| Volume | 0.110 mill |
| Avg. Vol. | 0.109 mill |
| % of Avg. Vol | 100.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIXT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIXT
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Latest Press Releases
2024-03-06 09:00:00 - Press Release
Bioxytran Announces Preprint Of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist
50% lesion clearance and regression of herpes zoster neuralgia within 48 – 72 hours boston, massachusetts, march 06, 2024 (globe newswire) -- bioxytran, inc. (bixt), (the “company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in researchgate entitled “association of rapid shingles lesion clearance and regression of herpes zoster neuralgia in case study using topical galectin-3 antagonism” showed a time lapsed clearance of the shingles lesions using a topical galectin-3 antagonist.
2024-02-21 08:00:00 - Press Release
Bioxytran's Oral Antiviral Drug To Enter Dose Optimization Clinical Trial For Covid-19
First medicinal chemistry of an antiviral drug made of sugars boston, massachusetts, feb. 21, 2024 (globe newswire) -- bioxytran, inc. (otcqb: bixt ), (the “company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with prolectin-m in its dose optimization trial.
2023-10-24 08:45:00 - Press Release
Bioxytran Gets Broad Patent Coverage On 60+ Viruses
Claims cover method of treating a viral infection with a lectin-binding carbohydrate boston, massachusetts, oct. 24, 2023 (globe newswire) -- bioxytran, inc. (bixt), (the “company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat covid-19 and other viral diseases, announced that the u.s patent and trademark office (uspto) has published the company's patent application wo2023178228a1 lectin-binding carbohydrates for treating viral infections.
2023-10-04 09:00:00 - Press Release
Bioxytran Interview At The Emerging Growth Conference
Boston, massachusetts, oct. 04, 2023 (globe newswire) -- bioxytran, inc. (otcqb: bixt) (the “company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat covid-19 and other viral causing diseases announced that bioxtran cco michael sheikh will be giving a presentation about the company's small pharma strategy on the emerging growth conference on october 5, 2023 at 10:15 am est. investors are encouraged to preregister to ensure you are able to attend the conference and receive any updates that are released. please submit your questions in advance to questions@emerginggrowth.com.
2023-09-14 09:41:00 - Press Release
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted In Prolectin-m
Boston, massachusetts, sept. 14, 2023 (globe newswire) -- bioxytran, inc. (bixt), (the “company”), a clinical stage biotechnology company developing oral drugs to treat covid-19 and other viral diseases, announced that its preprint article titled “evaluation of complex carbohydrates showing broad-spectrum antiviral activity against sars-cov-2, influenzas-a (h1n1), and human respiratory syncytial virus (hrsv) strain a2 in ‘in vitro' setting” (the “article”) contains data showing a significant reduction of viral load in covid-19, influenza (h1n1) and in human respiratory syncytial virus (rsv). prolectin-m (“pl-m”) and prolectin-i were the galectin antagonists used on these 3 viruses to produce the results set forth in the article.
Latest News
2023-03-29 16:04:53 - Proactive Investors
Bioxytran's positive Phase 2 trial results featured in ‘Vaccines' peer-reviewed journal
Bioxytran said positive top-line safety and efficacy results from the company's randomized, placebo-controlled Phase 2 clinical trial of its drug candidate Prolectin-M in 34 patients with mild-to-moderate COVID-19 have been featured in the peer-reviewed journal “Vaccines.” The company said in a statement that during the trial, an orally administered Galectin Antagonist in the form of a chewable tablet was administered for seven days.